Cardiac Fibroblasts regulate myocardium and coronary vasculature development via the collagen signaling pathway

Yiting Deng[2, #], Yuanhang He[1, 2, #], Juan Xu[2], Haoting He[2], Manling Zhang[3], Guang Li[2, *]

[1]Tsinghua University, Tsinghua medicine, School of Medicine, Beijing, China

[2]Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15201, USA

[3]Vascular Medicine Institute, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Keywords: Fibroblast, Ablation, Myocardium, Coronary vasculature, Single cell, Collagen, Extracellular matrix

[#] These authors contributed equally to the work

* Corresponding author: Guang Li: guangli@pitt.edu

Abstract:

The fibroblast (FB), cardiomyocyte (CM), and vascular endothelial cell (Vas_EC) are the three major cell types in the heart, yet their relationships during development are largely unexplored. To address this gap, we employed RNA staining of the FB marker gene *Col1a1* together with the CM marker gene *Actn2* and the Vas_EC marker gene *Cdh5* at different stages. This approach enabled us to discern the anatomical pattern of cardiac FBs and identify approximately one EC and four CMs directly interacting with each FB. Molecularly, through the analysis of single-cell mRNA sequencing (scRNA-seq) data, we unveiled collagen as the top signaling molecule derived from FBs influencing CM and Vas_EC development. Subsequently, we used a Pdgfra-CreER controlled diphtheria toxin A (DTA) system to ablate the FBs at different stages. We found that the ablation of FBs disrupted myocardium and vasculature development and led to embryonic heart defects. Using scRNA-seq, we further profiled the ablated hearts and identified molecular defects in their ventricular CMs and Vas_ECs compared to control hearts. Moreover, we identified a reduction of collagen in the ablated hearts and predicted collagen as the major signaling pathway regulating the differentially expressed genes in the ablated ventricular CMs. Finally, we performed both short-term and long-term fibroblast ablation at the neonatal stage. We found that short-term ablation caused a reduction in collagen and Vas_EC density, while long-term ablation may induce compensatory collagen expression without causing heart function reduction. In summary, our study has identified the function of fibroblasts in regulating myocardium and vasculature development and implicated an important role for the collagen pathway in this process.

Introduction:

Fibroblast is one of the most abundant cardiac cell types and plays important roles in normal heart function and pathological heart remodeling at the adult stage[1,2]. The fibroblast

composition in the heart has been analyzed with multiple approaches such as flow cytometry, with a focus on the left ventricle[3,4]. However, the anatomical location of fibroblasts in the heart along the developmental progression is still unclear. The heart in mice starts to develop into a four-chambered structure at E9.5. The atrial and ventricular chambers are connected by the atrioventricular canal (AVC), a transient structure that develops into the septum and valve cells[5,6]. Although the main fibroblast population does not develop until E13.5[7], fibroblast-like cells with the expression of *Col1a1* and other fibroblast genes start to develop in the AVC at E9.5[6].

CM and Vas_EC are the other two major cell types in the heart. Vas_EC develop at about the same time as FB, while CM develop before the appearance of FB at the chambers. FB has been shown to couple with CM through gap junctions and promote their maturation in human three-dimensional micro-tissue consisting of FB, CM, and EC[8]. In mice, epicardium-derived cells, mostly fibroblasts, have been reported to serve as guidepost cells by secreting the chemokine *Slit2*, guiding Vas_EC to the correct anatomical locations and promoting their maturation[9]. However, the lack of direct assessment of FB function *in vivo* prevents a comprehensive understanding of its role in regulating CM and Vas_EC development.

To study the function of a cell type rather than a gene, toxin genes such as NTR and DTA have been engineered into conditional ablation systems to eliminate specific groups of cells[10,11]. The DTA system has been used in mice to ablate cardiac progenitor cells and cardiomyocytes at early developmental stages[12]. Recently, a group of proliferating fibroblasts with the expression of *Postn* was identified in neonatal hearts. Further elimination of this cell population using the DTA ablation system showed its importance in promoting cardiomyocyte maturation[13]. Additionally, the DTA system has been used to ablate fibroblasts at the adult stage to assess their function in adverse cardiac remodeling[14,15]. However, the function of the primary fibroblast population during embryonic and neonatal stages remains unclear.

One of the major functions of FB is to synthesize and secrete extracellular matrix (ECM) proteins, which influence the behavior of other cell lineages[2,16]. The ECM is heterogeneous and composed of various types, such as collagen, fibronectin, elastin, and laminin, each with different subtypes. For example, collagen has 28 genes in vertebrates[17]. The ECM plays important roles in heart development and regeneration. For instance, *hyaluronan and proteoglycan link protein 1 (Hapln1)* is critical in regulating myocardial compaction and heart regeneration in zebrafish[18]. ECM has also been found to regulate mouse CM proliferation through β1-integrin signaling in a cell co-culture assay[19]. Moreover, collagen has been shown to be essential for heart regeneration in adult zebrafish and mice[20]. However, the heterogeneity and function of ECM genes in mouse heart development remain unclear.

In this study, we identified the anatomical patterns of cardiac FB, CM, and Vas_EC during embryonic development. We further examined the ligand-receptor interactions among these cell types and identified collagen as the top signaling pathway. Additionally, we investigated fibroblast function at different embryonic stages using a cell ablation system and analyzed the resulting molecular defects with scRNA-seq. Finally, we performed short-term and long-term fibroblast ablation at the neonatal stage and found that fibroblasts are dispensable for normal heart function development. In summary, this study provides a comprehensive understanding of the role of cardiac fibroblasts in myocardium and coronary vasculature development during embryonic and neonatal stages.

Results:

Cellular analysis of cardiac fibroblast anatomical location at different stages

To understand the spatial distribution of cardiac FBs along the developmental progression, we stained the fibroblast marker gene *Col1a1* on heart sections at different stages from E11.5 to P3. We observed a strong expression of *Col1a1* in epicardial cells at all analyzed stages (Fig. 1A). Inside the heart, we found *Col1a1*-positive cells enriched at the boundary of the atrial and ventricular regions in E11.5 and 12.5 hearts (Fig. 1A, S1), indicating their presence in the atrioventricular canal (AVC). By E13.5 and 14.5, the AVC cells had developed into valve structures, and the valve interstitial cells highly expressed *Col1a1* (Fig. 1A, S1). In the ventricles, a small proportion of *Col1a1*-positive cells were observed adjacent to the epicardium. In contrast, few *Col1a1* signal was found in the atrium at this stage (Fig. 1A). At E15.5 and 16.5, both ventricles were filled with *Col1a1*-positive cells, but the middle of the ventricular septum remained devoid of such cells (Fig. 1A, S1). FBs were also found in the atrium, but the signal at the tips of both atrial chambers was sparser (Fig. 1A, S1). The distribution of FBs at E17.5 and E18.5 was highly similar to that observed at E16.5 (Fig. 1A, S1). Furthermore, we analyzed the *Col1a1* signal in P0, P2 and P3 hearts and found dense *Col1a1* expression at the valves and in all four chambers (Fig. 1A, S1). In summary, this analysis revealed the spatial location of cardiac FBs along the developmental stages. Specifically, we found that the FBs developed first in the AVC and valve, then at the ventricular wall and atrial, and last at the ventricular septum (Fig. 1B).

Next, to analyze the spatial relationship between FB and other cardiac cell types, such as CM and EC, we performed RNA staining for their marker genes *Col1a1*, *Actn2*, and *Cdh5*. Consistent with the previously described pattern, we observed that FB were mainly enriched in valves and began to develop at the edges of ventricular chambers at E13.5. We also found that FB were intermingled with CM populations and spatially adjacent to ECs (Fig. S2A). Next, we stained the three lineage markers on E17.5 and P3 heart sections. We observed consistent results as E13.5 (Fig. 1C, S2B). Given that FB starts emerging at E13.5, we primarily quantified the contacts at E17.5 and P3. The quantification results showed that each FB was in contact with approximately one Vas_EC and four CMs at both stages. (Fig. 1C, D). These results suggest that cardiac FB are physically close to CMs and ECs, likely facilitating signal communications that impact their development.

Identification of heterogeneity in cardiac fibroblasts through the analysis of scRNA-seq data

Through the analysis of scRNA-seq data at 18 stages of developing hearts from CD1 mice, we investigated the expression of *Col1a1* and observed high expression in epicardial cells and fibroblasts (Fig. S3A). This is consistent with the findings from RNA staining (Fig. 1A). Subsequently, we reanalyzed the fibroblasts and identified four distinct populations comprising 13 clusters (Fig. S3D). Gene expression analysis revealed that all cells in these populations exhibited high expression of *Col1a1* (Fig. S3A). Moreover, through differential gene expression analysis between the populations, we discovered that one group of cells highly expressed *Hapln1* (Fig. S3B, D, E), a marker gene associated with valves. This indicates that these cells are valve interstitial cells. We also found another group of cells expressing *Cdh5* and *Tie1* (Fig. S3B, D, E), genes associated with the endothelial cell lineage. This suggests that these cells may represent fibroblasts derived from EDCs. Additionally, we identified a third group of fibroblasts expressing *Sox10* and *Phox2b* (Fig. S3B, D, E), genes associated with the neural crest cell lineage. This suggests that these cells may originate from neural crest cells. Finally, the rest of the cells formed a main population that likely represents epicardial cell-derived fibroblasts in the chambers, as they expressed *Tcf21* and other marker genes (Fig. S3D, E). Interestingly, further analysis of the cell cycle phases in these fibroblasts revealed that each

population consisted of cells in all three phases (Fig. S3C), indicating active proliferation during the early stages.

Next, to understand the anatomical location of these fibroblast populations, we performed RNA in situ hybridizations on postnatal heart sections. Firstly, we stained *Hapln1* together with *Dcn*, another Pan-fibroblast marker gene. We found that *Hapln1* was highly expressed in valves, and most of its signal overlapped with *Dcn* (Fig. S3Fi), suggesting its expression in valve interstitial cells (fibroblast-like cells in valves). We also stained *Cdh5* with *Col1a1* and observed a small cluster of cells with the expression of both genes, mostly located at the boundary of large vessels and ventricular chambers (Fig 2Fii). Finally, we co-stained *Sox10* and *Col1a1* expression (Fig. S3Fiii). As previously reported[21], we identified double positive cells in the outflow tract-derived large vessels (Fig. S3Fiii_1). However, interestingly, we also observed their presence in coronary vessels (Fig. S3Fiii_2), suggesting that these cells may have a broader function than previously thought. In summary, through the analysis of scRNA-seq data and in situ hybridizations, we identified different populations of cardiac FBs, which differentially expressed lineage genes likely from their precursor cells.

Molecular analysis of the signaling communications between fibroblast and the other cardiac cell types

To understand the interactions between FB and other cardiac cell types, we analyzed scRNA-seq data from developing CD1 hearts. By quantifying the number and strength of these interactions, we found that each cell type, except blood cells, had a similar number of interactions. However, in terms of interaction strength, FB exhibited the highest values compared to those of other cell types (Fig. 2A, Supplementary table S2). Next, we analyzed the signaling pathways secreted from FB to ventricular cardiomyocytes (Ven_CM) and Vas_EC. Interestingly, we found that the collagen pathway was the predominant pathway in both FB-VenCM and FB-VasEC interactions (Fig. 2B). In addition to collagen, we identified other signaling molecules such as laminin, Ptn, MK, Fn1, and Thbs, which are mostly extracellular matrix (ECM) proteins, as being secreted by FB to function in Ven_CM and Vas_EC (Fig. 2B). Within the collagen pathway, we further analyzed the detailed ligand-receptor interactions and found more interaction pairs in FB-VasEC than in FB-VenCM. Some interactions were shared between the two cell types, but most were distinct (Fig. 2C). Consistently, all the shared collagen types have been previously studied and found to play a crucial role in heart development, primarily by regulating AVC and vasculature development [22-26].

To better understand the role of ECM genes in FB_VasEC and FB_VenCM interactions, we analyzed their expressions (GO number, 0031012) in the chamber-derived fibroblasts (main_fb) using the CD1 and C57BL/6 scRNA-seq datasets from 18 stages[10] (Fig. S4A-F). Interestingly, we identified five groups of ECM genes that displayed stage or chamber specific expression in both datasets (Fig. S5-7, Supplementary table S3, 4). Specifically, we found one group of genes (G1) that was highly expressed at stages before E14.5. This gene group includes signaling molecules such as *Slit2* and *Wnt5a*, and collagen genes such as *Col13a1* and *Col26a1* (Fig. S5-7). We found the second group of genes (G2) were mainly expressed in the LV and RV from E14.5 onwards with a significant increase at the neonatal stage. This gene group includes collagen genes such as *Col5a1*, *Col6a1*, and *Col6a2*, and metalloproteinase genes such as *Adamts13* and *Adamts14*. Additionally, we identified the third group of genes were highly expressed in the LA and RA at most stages, which includes *Col12a1*, *Adamts1*, and *Adamts4*. Interestingly, *Fn1* also exists in this group, suggesting that it has an important function in atrial fibroblast development. Furthermore, we found the fourth group of genes were preferentially expressed in the other three chambers than the RA and were mainly expressed at late neonatal stages after P5 in certain chambers. This group of genes includes *Col4a4*, *Col4a5*, *Col4a6*, and *Ntn4*. Finally, we identified the fifth group of genes displayed universal expression

in all four chambers at most stages. This gene group includes *Col1a1*, *Col1a2*, and *Postn*, which are the ubiquitously expressed extracellular matrix genes (Fig. S5-7). In summary, we identified five groups of ECM genes displaying stage- and chamber-specific expression patterns in FB and observed that each gene group includes different collagen pathway members. Additionally, we analyzed the ligand-receptor interactions between FB and Ven_CM or Vas_EC at each stage. We found collagen pathway interactions were also enriched at most analyzed stages (Fig. S8, supplementary table S5, 6). These results together suggested the importance of collagen pathway in mediating the FB function in heart development.

Furthermore, we studied collagen deposition dynamics in developing hearts. We used collagen hybridizing peptide (CHP) to stain the total collagen after denaturing it via an antigen retrieval process. Consistent with *Col1a1* expression, we observed strong collagen signals in the epicardium at all analyzed stages (Fig. 2D). Interestingly, at E11.5, we observed collagen in both AVC and ventricular chambers. Given that fibroblasts in the chambers have not developed yet at this stage, the observed collagen is likely derived from other cell types, such as endocardial endothelial cells. At E14.5, we observed a strong collagen signal in the ventricular free walls, while the signal in the ventricular septum and atrium was relatively weaker. At E16.5, the collagen signal became brighter and denser throughout the heart, including the ventricular free wall, septum, and atrium. This distribution was slightly broader compared to the fibroblast distribution at the same stage (Fig. 1A). By P3, the collagen signal had further increased and formed stripe patterns (Fig. 2D). In summary, we found that the progression of collagen accumulation largely coincided with the development of FBs.

Lastly, we analyzed the signaling interactions among human cardiac cells using a human embryonic heart scRNA-seq dataset[27]. Consistent with the mouse analysis results, we identified strong interactions between FB and other cardiac cell types (Fig. 2E). Additionally, we found collagen to be the most enriched pathway in FB-VasEC interactions. However, interestingly, we did not observe the collagen pathway among the top enriched pathways in FB-VenCM interactions. This observation was confirmed in two other human embryonic heart scRNA-seq datasets[28,29]. These results suggest a partially similar mechanism underlying fibroblast regulation of heart development in both mice and humans.

Functional analysis of fibroblasts in embryonic heart development

To identify the right transgenic mice labeling the developing cardiac fibroblasts, we analyzed the expression of two well-known fibroblast marker genes, *Postn* and *Pdgfra*, in the CD1 scRNA-seq data. We observed that *Postn* was highly expressed in fibroblasts and mural cells. Among fibroblasts, *Postn* was expressed in all subpopulations (Fig. S9Ai). On the other hand, Pdgfra was specifically expressed in fibroblasts, although its expression was relatively lower than *Postn*, especially in postnatal staged atrial cells (Fig. S9Aii). To evaluate their efficiency in labeling fibroblasts, we bred Postn-CreER mice with Rosa-mTmG reporter mice and administered tamoxifen (200μg/g) to pregnant mice at E13.5 (Fig. S9Bi). We collected the hearts at E17.5 and observed only a small proportion of GFP-positive cells in the valves and septum (Fig. S9Bii), suggesting a low labeling efficiency from the Postn-CreER mice. In contrast, we conducted the same experiments using Pdgfra-CreER mice and observed a significant proportion of GFP-positive cells in both the valves and heart chambers (Fig 3A). These results demonstrate the efficient labeling capability of the Pdgfra-CreER; Rosa-mTmG mice.

To study the function of fibroblasts in heart development, we utilized a genetically encoded DTA system to ablate them, which involves the encoding of a toxin gene that induces apoptosis and allows for the ablation of target cells. Initially, we crossed floxed Rosa-DTA mice with Pdgfra-CreER mice and administered tamoxifen to pregnant female mice at E10.5. After 3

days, we harvested the embryos and observed that all the embryos with ablated fibroblasts (Pdgfra-CreER+/-; Rosa-DTA+/-) had perished, while the control embryos remained unaffected. This outcome indicates an essential role for fibroblasts in early-stage embryo development.

Subsequently, we administered tamoxifen to the female mice from the breeding pair at E13.5 and collected the embryonic hearts at E16.5 (Fig 3B). Our findings revealed that the ablated embryos exhibited smaller sizes compared to the control embryos, although the size of the ablated hearts did not significantly differ from that of the control hearts (Fig 3B). Additionally, we conducted TUNEL analysis to assess cell death in both control and ablated hearts and observed a significantly higher number of TUNEL-positive dots in the valve and chamber regions of the ablated hearts compared to the control hearts, confirming the successful ablation of fibroblasts in the experimental hearts (Fig. S10A, B). Furthermore, we examined the anatomical structure of the hearts but did not identify obvious defects in the ablated groups compared to control groups. However, we observed a reduction in endothelial cell density in the ablated hearts, as indicated by the CD31 staining signal (Fig 3C). Additionally, we measured the thickness of the compact and trabecular myocardium (Fig S10C). Our observations revealed that, compared to the control hearts, the ablated hearts exhibited a thinner left ventricular (LV) compact myocardium, while the thickness of the LV trabecular myocardium remained similar. Furthermore, we noted an elevated ratio of LV trabecular to compact myocardium in the ablated hearts compared to the control hearts (Fig 3D). However, no similar differences were observed in the right ventricle (RV). Finally, we examined cell proliferation post-ablation using pHH3 staining. We observed a reduction in pHH3-positive cells in the ventricular region, but not in the atrial region, of the ablated hearts compared to the control hearts (Fig. S10B). These results suggest that cell proliferation in ventricle was impaired following fibroblast ablation.

Next, we performed ablation at late embryonic stages by treating the pregnant mice with tamoxifen at E15.5 and harvested the embryos at E18.5 (Fig. S12A). We did not observe obvious differences in the size of the embryos and hearts between the ablated group and the control group (Fig. S12B). However, the CD31 staining of heart sections revealed large holes in the ablated atrium but not in the ablated ventricles or control hearts (Fig. S12C). Additionally, quantification of the compact and trabecular myocardium thickness in the LV and RV revealed a thinner LV compact myocardium (Fig. S12D). We also calculated the ratio of trabecular to compact myocardium thickness in the LV and RV and found that the ratio was increased in the RV but not in the LV of the ablated hearts compared to control hearts (Fig. S12E). These results indicated that both the LV and RV of the ablated hearts have subtle defects. Moreover, we analyzed cell proliferation by staining pHH3 and found no significant differences between the ablated and control ventricles (Fig. S12F).

Given that the animals did not show obvious morphological changes after one dose of tamoxifen treatment, we increased the tamoxifen treatment to three consecutive days, ranging from E15.5 to E17.5 (Fig 3E). We harvested the embryos at E18.5 and found that both the ablated embryos and their hearts were notably smaller in size compared to the controls (Fig 3E). Next, to confirm the ablation efficiency, we analyzed *Col1a1* expression with RNA staining and found that the ablated hearts lost almost all of their Col1a1 signal in the four chambers (Fig. S12G), indicating a high ablation efficiency with three doses of tamoxifen treatments. We further analyzed their valve structures and observed that the mitral valves in the ablated hearts appeared shorter than their counterparts in the control hearts. Specifically, we found that the mitral valve leaflets in control hearts were already connected to the papillary muscle, whereas the same valve leaflets in ablated hearts were not (Fig. S11A). Moreover, by conducting a staining analysis of CD31 in the control and ablated heart sections, we discovered that the ablated hearts exhibited a significantly lower endothelial cell density (Fig 3F, G). Further quantification of the LV compact and trabecular myocardium thickness showed a significant

reduction in the ablated hearts compared to control hearts (Fig 3G). However, interestingly, the ratio of trabecular to compact myocardium thickness in the LV did not differ between the control and ablated hearts, indicating a proportional reduction in both compact and trabecular myocardium thickness in the ablated hearts. Finally, we found that the ablated ventricles had less pHH3 signal than the control ventricles (Fig. S12F), indicating impaired cell proliferation in the ventricles following fibroblast ablation. These results together indicated that fibroblast plays an important role in embryonic heart development at all the analyzed stages.

Molecular analysis of the defects in the ablated embryonic hearts

Next, we performed scRNA-seq to analyze the defects in the ablated embryonic hearts. We utilized MULTI-seq to pool the control and ablated hearts from E16.5 and E18.5 (Fig. 4A). After filtering out low-quality cells based on our QC standards, we grouped the single cells from two experimental replicates using unsupervised methods and found a high degree of overlap (Fig. 4B, S13A). We then identified cell types and cell cycle phases within the single cells. In total, we identified eight cell types: Atrial_CM, Ven_CM, Vas_EC, Endo_EC, Mural_cell, FB, Epicardial cell, and Immune cell, along with three cell cycle phases (G1, S, G2M) in each cell type (Fig. 4C). Cells from both control and ablated conditions at E16.5 and E18.5 were present in each cell type. We further quantified the percentages of each cell type across conditions and found that the percentage of FB was significantly reduced in the ablated hearts at both stages, indicating effective ablation. Interestingly, we also observed a reduction in mural cells in the ablated hearts at both stages (Fig. 4D).

Next, we selected FB for further study of its cellular heterogeneity. By analyzing the expression of cardiac lineage genes, cell cycle phases, and sample sources, we identified four FB subpopulations (Fig. 4E). Specifically, we identified a group of valve fibroblasts (valve-fb) expressing valve mesenchymal cell genes such as *Hapln1*, a group of neural crest-derived fibroblasts (Neural_crest_fb) expressing *Sox10*, and a group of chamber-derived main fibroblasts (main_fb) expressing *Wt1* and *Tcf21* (Fig. S13B). All these FB groups contained cells from both control and ablated samples. In contrast, we identified another group of cells exclusively derived from the ablated samples, which expressed cell death-related genes (Fig. S13C). We named this group dying fibroblasts (dying_fb).

In addition to FB, we analyzed Ven_CM and found that cells from control and ablated hearts were highly overlapped on the UMAP plot (Fig. 4F). We quantified the proportions of cells at each cell cycle phase and found that the ablated samples had slightly higher percentages of cells in the G1 phase compared to control samples (Fig. 4G, S13D). We then performed differential gene expression analysis of control and ablated samples at E16.5 and identified a set of differentially expressed genes (Fig. 4H, supplementary table S7, 8). Gene ontology analysis of the upregulated genes in the ablated CMs showed enrichment in various pathways, including heart development, sarcomere organization, heart tube morphogenesis, and cell proliferation. In contrast, the downregulated genes were enriched in pathways related to chaperone-dependent protein folding, mitochondrial membrane permeability, fatty acid import, and mitochondrial ATP transmembrane transport (Fig. 4I). These results indicated that ablated Ven_CMs upregulated genes associated with heart development and cell proliferation while downregulating genes related to cell maturation, including those involved in mitochondrial function and cell metabolism.

Furthermore, we selected Vas_EC for further analysis. We did not observe distinct populations between control and ablated samples on the UMAP plot (Fig. 4J, S13E). However, through further differential expression analysis, we identified a group of genes with upregulated expression in the ablated samples (Fig. 4K, supplementary table S9). Gene ontology analysis of these genes revealed that they were primarily involved in immune response pathways, including

type I and II interferon production, interleukin-27-mediated pathways, NLRP3 inflammasome assembly, and cellular responses to exogenous dsRNA (Fig. 4L). These results suggest that Vas_EC exhibits a strong immune response following fibroblast ablation.

The signaling pathway defects in the ablated embryonic hearts

Next, we studied the signaling defects in the ablated hearts. Through the analysis of signaling pathways between main_fb and Vas_EC or Ven_CM, we found that the collagen pathway consistently ranked at the top in both control and ablated samples (Fig. 5A). We then stained for collagen levels using collagen hybridizing peptide and observed that collagen deposition was dramatically reduced in both the septum and ventricular wall of the ablated hearts compared to the control hearts (Fig. 5B).

Moreover, by analyzing the scRNA-seq data, we predicted the signaling ligands that may regulate the differentially expressed genes in control and ablated Ven_CM. Interestingly, the collagen pathway, which has four different collagen ligands on the list, emerged as a major regulator of these genes (Fig. 5C). In addition to collagens, we also identified other ligands, such as TGF-beta, IGF, and BMP, which were derived from FB and regulate the expression of differentially expressed genes in control and ablated Ven_CMs (Fig. 5C). We also predicted the receptors in Ven_CM for each ligand (Fig. S14A). Furthermore, we predicted the ligands in FB that regulate the differentially expressed genes in Vas_EC and identified several signaling molecules. These included the DTA pathway-related signal Hbegf, the inflammation-associated signal Il33, Wnt ligands (Wnt11, Wnt4, and Wnt5b), and collagen Col4a6 (Fig. 5D, S14B).

Finally, we predicted the signals from the dying_fb cells. Compared to normal main_fb and valve_like_fb, the dying_fb downregulated certain signaling pathways, such as the IGF pathway, EphA pathway, Tenascin pathway, and collagen pathway (Fig. 5E, S15A). Interestingly, they also upregulated several signaling pathways, including the EGF pathway, BMP pathway, VEGF pathway, and FGF pathway (Fig. 5E, S15B). Understanding the role of these altered signaling pathways from dying_fb in contributing to heart defects will be an interesting area for future research. Additionally, collagen and other ECM proteins are essential structural components. Their roles as structural proteins in heart development are critical and contribute to the heart phenotype observed in the ablated hearts.

Functional analysis of fibroblasts at neonatal stages

Next, we assessed the fibroblast function at neonatal stage. We treated the mice with tamoxifen at P1 and harvested them at P4 (Fig. S16A). We did not observe any obvious differences between the ablated and control hearts (Fig. S16B), consistent with a recent study that used the same strategy to ablate fibroblasts during a similar time period[30]. However, CD31 staining of heart sections revealed defects in the atrium, which had a thinner and segmented atrial wall (Fig. S16C). We further quantified the compact and trabecular myocardium in both the LV and RV but did not observe differences between control and ablated hearts (Fig. S16D). We also did not find differences in the ratio of trabecular to compact myocardium thickness between control and ablated hearts in the LV and RV (Fig. S16E). Finally, we analyzed cell proliferation by staining pHH3 and did not observe differences between the two conditions (Fig. S16F). Next, we increased the tamoxifen treatments to three times, ranging from P1 to P3, and collected hearts at P4 (Fig 6A). The heart morphology and size did not reveal obvious differences between control and ablated groups (Fig 6B). The CD31 staining revealed a reduction in endothelial cell density in the ablated hearts when compared to the control hearts (Fig 6C). These reductions in both LV and RV were further confirmed through quantifications (Fig 6D). Finally, we quantified the chamber thickness and cell proliferation. Similar to hearts treated with one dose of tamoxifen, we observed no apparent defects and cell proliferation changes in

ablated hearts with three days of tamoxifen treatments (Fig 6D, S16G). Furthermore, we stained the P4 hearts for collagen depositions. We observed that the ablated hearts had a sparser collagen signal and lost most of the stripe pattern in the septum compared to the control hearts. However, a significant amount of stripe-patterned collagen was still observed in the ventricular free wall, although the overall signal was sparser (Fig 6E). These collagens were likely derived from fibroblasts before ablation.

Lastly, we conducted a long-term analysis by administering tamoxifen to the mice from P3 to P5 and harvesting them at P17 or P18 (Fig. 6F). We observed that approximately two-thirds of the ablated mice had perished before P17 (Fig. 6G), and the surviving mice were significantly smaller than the control mice. Quantification revealed reduced heart rates and body weights, but a similar heart-to-body ratio in the ablated mice compared to controls (Fig. 6I). A detailed examination of the major tissues showed reduced organ sizes in the ablated mice, including smaller hearts, lungs, brains, kidneys, and livers (Fig. 6F, S18A). Additionally, we assessed mouse heart function using echocardiography before sacrificing them. Interestingly, we found that heart function, including ejection fraction (EF) and fractional shortening (FS), was not reduced in the ablated mice compared to controls (Fig. 6H, I). Furthermore, we evaluated collagen levels in the ablated hearts and did not observe a clear reduction or pattern change (Fig. S17). This finding contrasts with our observations at P4 (Fig. 6E) and suggests potential collagen expression compensation at later stages. In contrast, we found that the lungs of the ablated mice exhibited reduced collagen levels and larger empty spaces compared to the controls (Fig. S18B). These findings suggest that fibroblasts play a crucial role in the growth of multiple tissues during the neonatal phase. Additionally, it will be interesting to explore the mechanisms underlying the preservation of heart function when fibroblasts are eliminated in future studies.

Discussion:

In this study, we investigated the cellular and molecular interactions between FB and CM or Vas_EC, identifying collagen as the primary signaling molecule. We also analyzed the role of FB in embryonic heart development using a cell ablation system. Additionally, we employed scRNA-seq to identify the molecular defects in CM and Vas_EC within the ablated hearts. Finally, we examined the function of FB in neonatal heart development through both short-term and long-term ablation experiments. Altogether, our study represents the first comprehensive analysis of fibroblast function in heart development. The insights we gained from the study will not only enhance our understanding of the role of this major cardiac cell type in heart development but also shed light on its function in adult cardiac remodeling, as well as other tissue development and regeneration.

Through RNA staining of the three lineage genes, we found that each fibroblast directly interacts with approximately one Vas_EC and four CMs. Given that the quantification was conducted on 2D tissue sections, the number of contacts may be underestimated. Considering that Vas_EC and FB emerged around the same time, it will be important to understand in the future how their connections are established at the single-cell level and what these connections mean for the development of each lineage. Two studies in mice and zebrafish have shown that epicardial cells or epicardium-derived cells regulate Vas_EC development through the expression of *Hapln1* or *Slit2*[9,18]. It would be interesting to test whether collagen or other fibroblast-derived ECM proteins have similar roles. Additionally, *in vitro* culture experiments have demonstrated that fibroblasts interact with CMs through gap junction proteins or integrins

to regulate their proliferation[8,19]. Future studies should aim to clarify how these interactions are established *in vivo* and how they evolve during developmental progression.

Collagen, as the major ECM family, consists of 28 members[17]. In addition to collagen, there are many other types of ECM genes. Our scRNA-seq data revealed the temporal and spatial expression patterns of ECM genes in cardiac FBs. Future research should investigate their differential functions. For example, we found that most ECM genes in group 4 upregulate their expression by postnatal day 7, when mouse hearts begin to lose their regenerative capacity, suggesting a potential role in heart regeneration. This warrants further investigation. Additionally, while we have analyzed the collagen pathway as a whole in this study, our scRNA-seq analysis indicated that collagen genes in different groups exhibit distinct expression patterns. It will be essential to explore their unique roles in heart development in future studies. Furthermore, we found that collagen is the primary signaling molecule in FB_CM and FB_VasEC pairs in mice; however, we only observed it in FB_VasEC pair in humans. This discrepancy may be due to the loss of collagen receptors in human CMs, which merits further exploration.

The DTA-based cell ablation system has been used to ablate cardiac progenitors and cardiomyocytes before. It revealed that a robust regeneration response occurred after cell ablation at early stages[12]. However, in our study, based on the pHH3 staining, we did not observe an increase in cell proliferation after cell ablation. This could be due to multiple possibilities. First, the Pdgfra-CreER; Rosa-DTA-based ablation may be too severe to initiate the response to cell loss. Considering that ablation at E13.5 and ablation with three doses of tamoxifen at E15.5 both led to smaller embryos, the ablation of a large number of cells may compromise the compensation mechanisms. However, it is difficult to explain the embryos at E15.5 with one dose of tamoxifen treatment, which did not display obvious defects after ablation and have no increase in cell proliferation. Second, unlike cardiomyocytes, fibroblasts may have a limited compensatory response to their own ablation, although they can respond to CM loss at both neonatal and adult stages.

ScRNA-seq results revealed the upregulation of inflammation-related pathways in Vas_EC in the ablated hearts. It will be important to investigate whether these pathways are initiated by the ablation process or the loss of FBs in the future. Given that these pathways were primarily upregulated in Vas_EC but not in CM, this suggests a cell type-specific response. Studying the function of these signals in vascular development will be essential. Moreover, pathway analysis revealed both upregulation and downregulation of signaling pathways associated with dying fibroblasts. Further studies on these pathways are important, as they could offer valuable insights into the cell death process during normal heart development and heart injury and repair.

Fibroblast ablation at the neonatal stage led to two-thirds of the mice experiencing a lethal outcome, while the remaining mice developed a dwarf phenotype. Functional analysis of the mouse hearts showed preserved cardiac function post-ablation (Fig. 6H, I), suggesting that the lethal phenotype may be due to defects in other tissues, such as the lungs, which exhibited disrupted structures. Additionally, we conducted functional measurements at P18 under anesthesia in a small cohort of mice and found that the ablated mice exhibited a trend of improved heart function (Fig. S19). This finding indicates that fibroblasts may play a role in regulating heart function during the neonatal stage, aligning with observations in adult mice. In the adult stage, cardiac function was found to be superior in residential fibroblast-ablated mice compared to control mice following myocardial infarction or angiotensin II/phenylephrine (AngII/PE) treatments[14].

Methods:

Experimental methods

Mouse strains

The animal experiments have been approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC). CD1 male and female mice were purchased from Charles River Laboratories and bred in our laboratory to generate embryos and neonatal pups at specific stages for RNA staining experiments. The transgenic mice, including Rosa26-mTmG (Strain #:007676)[31], Pdgfra-CreERT2 (Strain #:032770)[32], Postn-CreER (Strain #:029645)[33], and ROSA26-eGFP-DTA (Strain #:032087)[10], were ordered from the Jackson Laboratory.

Tamoxifen treatment and mouse dissection

The male and female mice of specific strains were bred together. The default dosage of 200μg of tamoxifen per gram of body weight (200μg/g) was given to pregnant mice through oral gavage, and neonatal mice were given 10μg/g of tamoxifen by direct injection into their stomach to induce Cre activity[13]. The pregnant mice and neonatal pups were euthanized using CO2 and decapitation-based methods, respectively. The mouse hearts were isolated following the standard procedure described previously and were directly embedded in OCT without fixation for RNA staining or fixed at 4% paraformaldehyde for other experiments, such as immunofluorescence staining.

Proximity ligation in situ hybridization (PLISH)

PLISH was performed following a published protocol[34]. Specifically, the embryonic or postnatal mouse hearts were embedded in OCT (Sakura, 4583) without fixation. After sectioning at a thickness of 10μm, the tissue sections were treated with post-fix medium (RNase-free PBS with 3.7% formaldehyde and 0.1% DEPC) followed by 0.1mg/ml pepsin treatment (RNase-free H2O with 0.1mg/ml pepsin and 0.1M HCl). After dehydration, the sections were sealed with hybridization chambers (Invitrogen, S24732) and hybridized with H probes (supplementary table S1) in Hybridization Buffer (1 M NaTCA, 5 mM EDTA, 50 mM Tris pH 7.4, 0.2 mg/mL Heparin). Next, after being treated with circularization reaction and rolling cycle amplification, the samples were hybridized with detection probes conjugated with Cy3 or Cy5 fluorophore. Finally, the samples were stained with DAPI (Invitrogen, D1306), mounted with fluoromount-g (SouthernBiotech, OB100-01), and imaged under confocal microscopy (Leica TSC SP8).

RNAscope Multiplex Fluorescent V2 Assay

The RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics, 323270) was performed according to the manufacturer's manual. Briefly, the tissue sections were fixed in pre-chilled 4% PFA (Electron Microscopy Sciences,15710) at 4℃ for 1 hour. After progressive dehydration, the sections were sequentially treated with hydrogen peroxide for 10 minutes and protease IV for 15 minutes (for embryonic) or 20 minutes (for postnatal) at room temperature (RT). After that, the samples were hybridized to gene-specific Z probes for 2 hours at 40℃ using the HybEZ II Hybridization system (ACD, 321721). Following further signal amplification, the hybridization signals were detected with TSA Vivid Fluorophores. The samples were then stained with DAPI and mounted with ProLong Gold Antifade Mountant (Invitrogen, P36930), and imaged under confocal microscopy (Leica TSC SP8). The RNAscope probes used in the study are Mm-Col1a1-C2 (319371-C2), Mm-Actn2 (569061), and Mm-Cdh5-C3 (312531-C3).

Quantification of the interacting cells

Based on the RNA scope staining results, the direct contacts between fibroblasts and cardiomyocytes as well as endothelial cells was quantified. Given that the fibroblast starts to emerge at E13.5, we mainly quantified the contacts at E17.5 and P3. Approximately 100 fibroblasts from the left ventricular wall at each stage were selected, and the number of *Actn2*$^{+}$ and *Cdh5*$^{+}$ cells surrounding each fibroblast was counted respectively.

Immunofluorescence staining

The immunofluorescence staining was performed following a standard procedure. Briefly, mouse hearts were fixed in 4% PFA overnight before embedding in OCT. Afterwards, the samples were sectioned at 10μm and briefly washed in PBS to clean the OCT. The sections were then blocked for 1 hour in blocking buffer (10% goat serum, 1% BSA, 0.1% Tween 20) and incubated with primary antibodies in the primary antibody buffer (1% BSA in PBST) at 4℃ overnight. On the second day, the samples were stained with fluorophore-conjugated secondary antibodies in blocking buffer for 1 hour at room temperature. Finally, the samples were stained with DAPI, mounted with fluoromount-g, and imaged with a confocal microscope. The primary antibodies used in the study include anti-CD31 (BD, # 550274), and anti-pHH3-488 (abcam, #ab197502). The secondary antibodies used are Goat Anti-Rabbit IgG-488 (ThermoFisher, # A-11008) and Goat Anti-Rabbit IgG-647 (ThermoFisher, #A21247).

Collagen staining

Fresh frozen sections from embryonic and postnatal mouse hearts were fixed in 4% PFA in 1X PBS for 15 minutes at room temperature (RT). After that, the sections were soaked in a sodium citrate-based solution (distilled water with 10mM sodium citrate and 0.5% Tween-20, HCl was added to adjust pH to 6.0) for antigen retrieval, which was performed in a steamer for 30 minutes. Subsequently, the sections were incubated with 20 μM biotin-conjugated collagen hybridizing peptide (Advanced Biomatrix, 50-196-0307) in 1X PBS at 4℃ overnight. The next day, streptavidin-cy5 (Invitrogen, SA1011) was used (1:500 in 1X PBS with 1% BSA) for 1 hour at RT. Finally, the samples were stained with DAPI, mounted with FLUOROMOUNT-G, and imaged under a confocal microscope.

TUNEL staining

TUNEL staining was performed following the manufacturer's protocol (Roche, 11684795910). Briefly, mouse hearts were embedded and sectioned as described in the immunofluorescence staining procedure. After fixation with 4% Paraformaldehyde in PBS for 20 minutes and three washes with PBS, the sections were incubated in permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 2 minutes on ice, followed by two PBS rinses. Subsequently, 60 μl of TUNEL reaction mixture was added to each section, and they were incubated in a humidified atmosphere for 1 hour at 37℃ in the dark. Finally, the sections were washed with PBS three times, stained with DAPI, mounted with fluoromount-g, and imaged with a confocal microscope.

Single cell mRNA-sequencing experiments

ScRNA-seq was performed following the MULTI-seq procedure previously reported[35,36]. Briefly, tamoxifen-treated E16.5 and E18.5 Pdgfra-CreER; Rosa-DTA mouse embryos were harvested on the same day. Since the ablated mouse embryos at both stages were smaller than the control embryos, we selected one control and one ablated embryo from each stage for heart dissection. The genotype of the selected embryos was further validated using PCR. The hearts, with four chambers, were dissociated into single cells and labeled with MULTI-seq barcodes. The pooled libraries were then loaded onto the 10X Genomics Chromium iX and profiled using

the single-cell 3' V3.1 kit. The generated libraries were sequenced on the Illumina NovaSeq X Plus platform. The experiments were repeated twice.

Echo imaging

Echocardiography was performed using a standard protocol[37]. Briefly, heart function of awake mice at P17 was assessed using the Vevo 2100 micro imaging platform (FUJIFILM Visual Sonics Inc., Canada). The measurements were conducted at the level of papillary muscle in M mode. Heart rates, left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic dimensions (LVESD) were calculated from the 2D short-axis view.

Statistical analysis

To quantify pHH3 signal, compact, and trabecular myocardium thickness, we used two to three sections from each heart and more than three hearts per genotype. The exact number of embryos profiled can be found in each figure legend. Statistical analyses were conducted using ImageJ and Prism 9 software, employing a two-tailed Student's t-test to compare groups. P-values below 0.05 were considered significant.

Data analysis

Data Availability

The newly generated scRNA-seq datasets have been deposited in the Gene Expression Omnibus (GEO) under the accession number GSE272048. Please use this secure token (sdcxiewmxfyztar) to review the data. The scRNA-seq datasets from CD1 and C57BL/6 mouse hearts were generated in a previous study and can be downloaded from the GEO database using the accession number GSE193346[36]. The human scRNA-seq data were obtained from GEO or the European Genome-Phenome Archive (EGA) under the accessions GSE106118 and EGAS00001003996[27-29] for CellChat analysis.

ScRNA-seq data analysis

ScRNA-seq data were mapped to the mouse genome mm10 using CellRanger and further de-multiplexed with the R package deMULTIplex[35]. Cell types in the newly generated scRNA-seq data were annotated using lineage genes previously published by our team[36]. We performed quality control by removing cells with fewer than 200 genes and those with more than 40% mitochondrial content. Experimental batch integration was conducted using Harmony 1.2.0[38], followed by unsupervised clustering with Seurat V5[39]. Next, we utilized the Cell Cycle Scoring function in Seurat to annotate the cell cycle phases for each individual cell. Finally, we applied the FindMarkers function in Seurat with default settings to identify genes that were differentially expressed in Ven_CM or Vas_EC under control and ablation conditions.

Extracellular matrix genes expression analysis

We downloaded the extracellular matrix genes from the Jackson Laboratory under the term "extracellular matrix" and gene ontology ID 0031012 (https://www.informatics.jax.org/go/term/GO:0031012; Download date: 2023-07-07). After downloading, we cleaned the gene list by removing duplicates and filtering out genes with null expression, resulting in a total of 440 genes. Next, we assessed the enrichment of each gene in the main population of fibroblasts at each stage and chamber using the R package AUCell[40], with heatmaps drawn with the R package ggplot2 (Fig 9, S9, S10).

Ligand-receptor interaction analysis

To identify ligand-receptor interactions across stages and zones for fibroblasts and cardiomyocytes, we analyzed relevant subsets of the CD1 data, including the main population of FB, ventricular CM, and Vas_EC using CellPhoneDB v3.34[41]. We used a p-value threshold of 0.2 and ran the analysis with 10 threads, while keeping the rest of the parameters at their default settings. The significant mean value of all interactive partners (log2) and enrichment p-values (-log10) obtained from the CellPhoneDB outputs were plotted as dotplots in R.

Cellchat analysis

The Seurat object containing mouse CD1 single-cell mRNA sequencing data was converted into a CellChat object in R. Default settings in CellChat 1.6.1[42] were used to identify the number and strength of interactions among cell types. FB were designated as sender cells, while Ven_CM and Vas_EC were designated as receiver cells to identify signaling between these related cell types. The same default settings were applied to analyze signaling pathways among human cardiac cell types. For pathway analysis in control and DTA-ablated cardiac cells, their respective scRNA-seq objects were utilized.

NicheNet analysis

Nichenetr 2.1.5[43] was used for the analysis with default settings. First, we identified differentially expressed genes between control and ablated cells. Due to the varying number of recovered cells in each cell type under different conditions, we selected different staged samples for comparison and assessed their consistency across the remaining samples. For Ven_CMs, we used the E16.5_control_1 and E16.5_DTA_1 samples, while for Vas_EC, we included all four E16.5 samples. Next, we designated the control sample as the background condition and the ablated sample as the experimental condition, using main_fb as the sending cells and Ven_CM or Vas_EC as the receiving cells to predict their regulatory potential.

Acknowledgements

We'd like to thank all the members in the Li laboratory for their insightful discussions of this work. We are thankful for Dr. Wei Feng for his help on the MULTI-seq experiment. This research was supported in part by the University of Pittsburgh Center for Research Computing, RRID:SCR_022735, through the resources provided. Specifically, this work used the HTC cluster, which is supported by NIH award number S10OD028483.

Sources of Funding

This work was supported by R00HL133472 and DP2HL163745 from the NIH and the CMRF grant from the University of Pittsburgh.

Author Contributions

Y.D., Y.H., G.L. designed the experiments; Y.D. analyzed the ablated hearts with different assays; J.X. bred the mice, treated them with tamoxifen, and harvested the hearts from embryonic and neonatal mice. Y.H. performed the RNAScope and collagen staining experiments, Y.H. and G.L. performed the PLISH experiments; Y.D. performed the scRNA-seq experiment. H.T. and G.L. analyzed the scRNA-seq data; M.Z. and J.X. has performed the Echo scanning and data analysis. Y.D., Y.H., H.T., and G.L. prepared the manuscript; All the authors edited the manuscript.

Competing interests

The authors declare no competing interests.

Figure Legends

Fig 1. Anatomical location of cardiac fibroblasts and their spatial relationship with cardiomyocytes and endothelial cells at different stages. (A) RNA staining of *Col1a1* revealed the spatial pattern of cardiac fibroblasts at different developmental stages. Scale bar=500μm. (B) The development of cardiac fibroblasts can be grouped into four phases. (C) RNA staining analysis of *Col1a1*, *Actn2*, and *Cd31* revealed the spatial proximity of FB, CM, and EC in E17.5 hearts. (D) Quantification of the number of CMs and ECs that contact with each FB (n=100). Scale bar=500μm and 100μm in the whole heart sections and enlarged sections, respectively.

Fig 2. Molecular analysis of fibroblast communications with other cardiac cell types in developing hearts. (A) The number and strength of interactions among different cardiac cell types identified from scRNA-seq data. (B) The top signaling pathways derived from FB that impact Ven_CM and Vas_EC development. (C) The detailed ligand-receptor interactions in the collagen pathway between FB and Ven_CM or Vas_EC. (D) Collagen was visualized using CHP staining in mouse hearts at E11.5, E14.5, E16.5, and P3. Scale bar=500μm and 150μm in the whole heart sections and enlarged sections, respectively. (E) The signaling interactions and top pathways between FB and Ven_CM or Vas_EC in primary human hearts.

Fig 3. Functional analysis of FB in embryonic heart development. (A) Diagram of the lineage tracing experiments and the tracing results. Scale bar = 500μm. (B) The ablated embryos treated with tamoxifen at E13.5 were smaller than control embryos, but the ablated hearts were not obviously different from the control hearts. Scale bar=1mm. (C) Representative CD31 staining images in control and ablated hearts. The zoomed-in images showed a reduction of CD31 positive area in the ablated hearts compared to controls. (D) Quantification of the thickness of compact and trabecular myocardium (19 sections from 7 ablated hearts and 20 sections from 7control hearts), and CD31 positive areas in control and ablated hearts (15 sections from 5 ablated and 15 sections from 5 control hearts). The littermate control mice include both double-negative and Pdgfra-CreER+/− mice. (E) The ablated mice and hearts treated with tamoxifen at E15.5 were smaller than controls. (F) CD31 staining analysis of control and ablated hearts. (G) Quantification of the compact and trabecular myocardium thickness, and CD31 positive areas in control and ablated hearts (12 sections from 4 ablated hearts and 12 sections from 4 control hearts.). The littermate control mice include both double-negative and Pdgfra-CreER+/− mice. Scale bar =500μm in the whole heart sections and 100 μm in the zoomed in images. * represents $p<0.05$; ** represents $p<0.01$.

Fig 4. Single cell analysis of the embryonic heart defects after fibroblast ablation. (A) Diagram of the MULTI-seq experiments to profile control and ablated hearts at two developmental stages. (B) The scRNA-seq data from two replicates are highly consistent. (C) UMAP plots of scRNA-seq data labeled by cell type, cell cycle phase, and genotype. (D) Quantification of the FB and mural cell percentages at each conditions. (E) Detailed analysis of the fibroblast population revealed four groups, including a dying fibroblast subpopulation. (F) UMAP plot of Ven_CMs from different conditions. (G) Quantification of the different cell cycle phased Ven_CMs under each condition. (H, I) Heatmap and pathway enrichment of genes that are differentially expressed in control and ablated Ven_CMs at E16.5. (J) UMAP plot of Vas_EC labeled by conditions. (K, L) Heatmap and pathway enrichment of genes that were upregulated in ablated

Vas_ECs compared to control Vas_ECs. The littermate control mice at both stages were Pdgfra-CreER+/−.

Fig 5. Identification of signaling defects in ablated hearts. (A) The top signaling pathways between FB and Ven_CM or Vas_EC in control and ablated hearts. (B) CHP staining revealed a significant reduction in collagen deposition in ablated hearts compared to control hearts. (C, D) Regulatory analysis predicted the ligands that regulate the genes differentially expressed in control and ablated Ven_CMs and Vas_EC. (E) Representative signaling pathways that were downregulated or upregulated in the dying FBs.

Fig 6. Short term and long term functional analysis of fibroblasts at neonatal stage. (A) Diagram of the experiment to ablate fibroblasts with three doses of tamoxifen treatment from P1 to P3. Scale bar=1cm. (B) No obvious size difference was observed between control and ablated hearts. (C) Representative images of control and ablated hearts stained with CD31. (D) Quantification of the compact and trabecular myocardium thickness and CD31 positive areas in ventricular at control and ablated hearts (12 sections from 4 ablated hearts and 12 sections from 4 control hearts.). (E) Collagen accumulation in control and ablated hearts at P4. Collagen was visualized using CHP staining. The littermate control mice were Pdgfra-CreER+/−. Scale bar=500μm and 150μm in the whole heart sections and enlarged sections, respectively. (F) Tamoxifen was given from P3 to P5 to ablate the fibroblasts and hearts were collected at P17 for analysis. The littermate control mice were Pdgfra-CreER+/−. (G) The percentage of mice died at different days. (H) Representative echo images of the control and ablated hearts. (I) Quantification of the heart rate, body weight, and heart function in control and ablated mice at P17. * represents $p<0.05$; ** represents $p<0.01$; *** represents $p<0.001$.

Legends for Supplemental Figures

Supplementary Fig. S1: (A) Analysis of fibroblast anatomical pattern by staining Col1a1 at different stages. Scale bar=500μm.

Supplementary Fig. S2: (A, B) RNA staining of *Col1a1*, *Actn2*, and *Cd31* expression at E13.5 and P3 heart sections. Scale bar=500μm and 100μm in the whole heart sections and enlarged sections, respectively.

Supplementary Fig. S3: ScRNA-seq identified distinct fibroblast populations. (A) UMAP plot of *Col1a1* expression in cardiac cells. (Bi-iv) UMAP plots of *Col1a1* and representative cluster-specific genes expression in cardiac fibroblasts. (C) UMAP plot of fibroblasts labeled by cell cycle phases. (D) Diagram of the four types of cardiac fibroblasts. (E) The top 10 genes expressed in each group of cardiac fibroblasts. (Fi-iii) Identification of the anatomical location of each fibroblast population through RNA staining. Scale bar=500μm and 250μm in the whole heart images and the images with enlarged areas, respectively.

Supplementary Fig. S4: Heterogeneity analysis of cardiac fibroblasts. (A, B) The cell types and main_fb population in CD1 scRNA-seq dataset. (C, D) The cell types and main_fb population in C57BL/6 scRNA-seq dataset. (E, F) The main_fb cells labeled by stage and chamber.

Supplementary Fig. S5. The expression pattern of extracellular matrix genes in the main population of cardiac fibroblasts. (A) Clustering analysis of the ECM gene expression enrichments. (B) The group of genes (G1) that were highly expressed at early staged fibroblasts in all four zones. (C) The group of genes (G2) that were highly expressed in LV and RV at late embryonic and neonatal stages. (D) The genes (G3) that were preferentially expressed in LA and RA. (E) The genes (G4) that were highly expressed in LA, LV, and RV at neonatal stage.

Supplementary Fig. S6: (A, B) The expression pattern of a group of genes (G5) that displayed expression in all four chambers of FBs (CD1 mice) at late embryonic and neonatal stages.

Supplementary Fig. S7: The expression pattern analysis of extracellular matrix genes in C57BL/6 FBs. (A) Unsupervised clustering analysis of extracellular matrix genes expression in C57BL/6 FBs. (B) The groups of genes that display stage or zone-specific expression pattern.

Supplementary Fig. S8: (A, B) The ligand-receptor interactions between FBs and ventricular CM or Vas_EC at each stage.

Supplementary Fig. S9: (Ai, ii) UMAP plots of *Postn* and *Pdgfra* expression in cardiac cells and cardiac fibroblasts. (B) (i) The workflow to lineage trace the Postn-CreER;mTmG labeled cells. (ii) A few cells in valves and septum were labeled in Postn-CreER: Rosa26-mTmG mouse hearts. Scale bar=500μm.

Supplementary Fig. S10: (A) Representative images of TUNEL staining in control and Pdgfra-CreER; Rosa-DTA hearts. (B) Quantification of TUNEL (7 sections from 2 ablated hearts and 8 sections from 2 control hearts) and pHH3 signals (5 sections from 2 ablated hearts and 4 sections from 2 control hearts). (C) Representative images illustrating the quantification of compact and trabecular myocardium thickness in control and ablated hearts at E16.5. Scale bar=500μm and 100μm in the whole heart images and the images with enlarged areas, respectively.

Supplementary Fig. S11: Comparative analysis of valve development in control and fibroblast-ablated hearts at E18.5 (A). Scale bar=500μm and 100μm in the whole heart images and the images with enlarged areas, respectively.

Supplementary Fig. S12: Quantification of the defects in control and ablated hearts with one dose of tamoxifen treatment at E15.5. (A) Diagram of the experimental procedure with one dose of tamoxifen being administered at E15.5. (B) No obvious size differences were observed in the ablated embryos and hearts compared to controls. (C) CD31 staining analysis of control and ablated hearts. The littermate control mice were Pdgfra-CreER+/−. (D) Quantification of the compact and trabecular myocardium thickness in LV and RV (6 sections from 2 ablated hearts and 5 sections from 2 control hearts). (E) Quantification of the ratio of trabecular to compact myocardium in LV and RV. (F) Quantification of pHH3 positive cells in control and ablated ventricles (6 sections from 2 ablated hearts and 5 sections from 2 control hearts for one dose of tamoxifen treated group, while 12 sections from 4 ablated hearts and 12 sections from 4 control hearts for three doses of tamoxifen treated group). (G) RNA staining analysis of *Col1a1* in control and ablated hearts with three doses of tamoxifen treatments. The *Col1a1* signal was dramatically reduced in the ablated hearts. * represents $p<0.05$; ** represents $p<0.01$. Scale bar=500μm.

Supplementary Fig. S13: (A) QC plots of the filtered single cells including the total number of genes, total number of mRNA, and percentage of mitochondria genes. (B) The expression pattern of representative genes to identify fibroblast subpopulations. (C) The genes highly and specifically expressing in the dying_fb cells. (D, E) UMAP plots of Ven_CM and Vas_EC labeled by cell cycle phases.

Supplementary Fig. S14: The predicted ligand-receptor interaction potentials between main_fb and Ven_CM or Vas_EC.

Supplementary Fig. S15: The signaling pathways that were found to reduce or increase their strengths in the dying_Fb compared to the main_fb and valve_like_fb.

Supplementary Fig. S16: Quantification of the defects in control and ablated hearts at neonatal stage with one dose of tamoxifen treatment. (A) Diagram of the experimental procedure with tamoxifen treatment at P1. (B) No obvious size differences were observed in the ablated hearts compared to control hearts. (C) Representative images of control and ablated hearts stained with CD31. The defects in the right atrium from ablated hearts were pointed out by an arrow. The littermate control mice include both double-negative and Pdgfra-CreER+/− mice. Scale bar = 500μm. (D) Quantification of the compact and trabecular myocardium thickness in LV and RV (6 sections from 3 ablated hearts and 4 sections from 2 control hearts). (E) Quantification of the ratio of trabecular to compact myocardium in LV and RV after one dose of tamoxifen treatment (6 sections from 3 ablated hearts and 4 sections from 2 control hearts). (F) Quantification of pHH3 positive cells in ventricular in control and ablated hearts after one dose of tamoxifen treatment (6 sections from 3 ablated hearts and 8 sections from 4 control hearts). (G) Quantification of pHH3 positive cells in ventricular in control and ablated hearts after three doses of tamoxifen treatments (12 sections from 4 ablated hearts and 12 sections from 4 control hearts). * represents $p<0.05$; ** represents $p<0.01$.

Supplementary Fig. S17: (A, B) Collagen accumulation in control and ablated hearts at P18. Scale bar=500μm and 150μm in the whole heart sections and enlarged sections, respectively.

Supplementary Fig. S18: (A) Representative images of brain, lung, kidney, and liver from control and Pdgfra-CreER; Rosa-DTA mice at P18 with tamoxifen treatment at P3 to P5. Scale bar = 5mm. (B) Collagen staining of lung from control and ablated mice at P18. The littermate control mice were Pdgfra-CreER+/−. Scale bar=500μm and 150μm in the whole heart sections and enlarged sections, respectively.

Supplementary Fig. S19: Echocardiographic analysis of heart function in anesthetized control and ablated mice at P18. The littermate control mice were Pdgfra-CreER+/−.

Legend for Supplementary Tables:

Supplementary Table 1: Primer sequences for PLISH probes

Supplementary Table 2: The interaction strength values among the different cell types in Figure 2A.

Supplementary Table 3: The enrichment score of extracellular matrix genes in CD1 main population fibroblasts.

Supplementary Table 4: The enrichment score of extracellular matrix genes in C57BL/6 main population fibroblasts.

Supplementary Table 5: The list of ligand-receptor interactions between the main population of fibroblast and ventricular cardiomycocytes in CD1 dataset.

Supplementary Table 6: The list of ligand-receptor interactions between the main population of fibroblast and Vas_EC in CD1 dataset.

Supplementary Table 7: The list of genes that differentially expressed in control and ablated Ven_CMs at e16.5 stage.

Supplementary Table 8: The list of genes that differentially expressed in control and ablated Ven_CMs at e18.5 stage.

Supplementary Table 9: The list of genes that differentially expressed in control and ablated Vas_ECs.

References:

1 Hall, C., Gehmlich, K., Denning, C. & Pavlovic, D. Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease. *J Am Heart Assoc* **10**, e019338, doi:10.1161/JAHA.120.019338 (2021).

2 Tallquist, M. D. & Molkentin, J. D. Redefining the identity of cardiac fibroblasts. *Nat Rev Cardiol* **14**, 484-491, doi:10.1038/nrcardio.2017.57 (2017).

3 Zhou, P. & Pu, W. T. Recounting Cardiac Cellular Composition. *Circ Res* **118**, 368-370, doi:10.1161/CIRCRESAHA.116.308139 (2016).

4 Pinto, A. R. *et al.* Revisiting Cardiac Cellular Composition. *Circ Res* **118**, 400-409, doi:10.1161/CIRCRESAHA.115.307778 (2016).

5 de Vlaming, A. *et al.* Atrioventricular valve development: new perspectives on an old theme. *Differentiation* **84**, 103-116, doi:10.1016/j.diff.2012.04.001 (2012).

6 O'Donnell, A. & Yutzey, K. E. Mechanisms of heart valve development and disease. *Development* **147**, doi:10.1242/dev.183020 (2020).

7 Tallquist, M. D. Developmental Pathways of Cardiac Fibroblasts. *Cold Spring Harb Perspect Biol* **12**, doi:10.1101/cshperspect.a037184 (2020).

8 Giacomelli, E. *et al.* Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease. *Cell Stem Cell* **26**, 862-879 e811, doi:10.1016/j.stem.2020.05.004 (2020).

9 Quijada, P. *et al.* Coordination of endothelial cell positioning and fate specification by the epicardium. *Nat Commun* **12**, 4155, doi:10.1038/s41467-021-24414-z (2021).

10 Ivanova, A. *et al.* In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A. *Genesis* **43**, 129-135, doi:10.1002/gene.20162 (2005).

11 Curado, S., Stainier, D. Y. & Anderson, R. M. Nitroreductase-mediated cell/tissue ablation in zebrafish: a spatially and temporally controlled ablation method with applications in developmental and regeneration studies. *Nat Protoc* **3**, 948-954, doi:10.1038/nprot.2008.58 (2008).

12 Sturzu, A. C. *et al.* Fetal Mammalian Heart Generates a Robust Compensatory Response to Cell Loss. *Circulation* **132**, 109-121, doi:10.1161/CIRCULATIONAHA.114.011490 (2015).

13 Hortells, L. *et al.* A specialized population of Periostin-expressing cardiac fibroblasts contributes to postnatal cardiomyocyte maturation and innervation. *Proc Natl Acad Sci U S A* **117**, 21469-21479, doi:10.1073/pnas.2009119117 (2020).

14 Kuwabara, J. T. *et al.* Consequences of PDGFRalpha(+) fibroblast reduction in adult murine hearts. *Elife* **11**, doi:10.7554/eLife.69854 (2022).

15 Kaur, H. *et al.* Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice. *Circ Res* **118**, 1906-1917, doi:10.1161/CIRCRESAHA.116.308643 (2016).

16 Ivey, M. J. & Tallquist, M. D. Defining the Cardiac Fibroblast. *Circ J* **80**, 2269-2276, doi:10.1253/circj.CJ-16-1003 (2016).

17 Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. *J Cell Sci* **123**, 4195-4200, doi:10.1242/jcs.023820 (2010).

18 Sun, J. *et al.* hapln1 Defines an Epicardial Cell Subpopulation Required for Cardiomyocyte Expansion During Heart Morphogenesis and Regeneration. *Circulation* **146**, 48-63, doi:10.1161/CIRCULATIONAHA.121.055468 (2022).
19 Ieda, M. *et al.* Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. *Dev Cell* **16**, 233-244, doi:10.1016/j.devcel.2008.12.007 (2009).
20 Simoes, F. C. *et al.* Macrophages directly contribute collagen to scar formation during zebrafish heart regeneration and mouse heart repair. *Nat Commun* **11**, 600, doi:10.1038/s41467-019-14263-2 (2020).
21 Ali, S. R. *et al.* Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. *Circ Res* **115**, 625-635, doi:10.1161/CIRCRESAHA.115.303794 (2014).
22 Kruithof, B. P., Krawitz, S. A. & Gaussin, V. Atrioventricular valve development during late embryonic and postnatal stages involves condensation and extracellular matrix remodeling. *Dev Biol* **302**, 208-217, doi:10.1016/j.ydbio.2006.09.024 (2007).
23 Lincoln, J., Alfieri, C. M. & Yutzey, K. E. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. *Dev Dyn* **230**, 239-250, doi:10.1002/dvdy.20051 (2004).
24 Lincoln, J., Florer, J. B., Deutsch, G. H., Wenstrup, R. J. & Yutzey, K. E. ColVa1 and ColXIa1 are required for myocardial morphogenesis and heart valve development. *Dev Dyn* **235**, 3295-3305, doi:10.1002/dvdy.20980 (2006).
25 van der Kooi, A. J. *et al.* Cardiac and pulmonary investigations in Bethlem myopathy. *Arch Neurol* **63**, 1617-1621, doi:10.1001/archneur.63.11.1617 (2006).
26 Lockhart, M., Wirrig, E., Phelps, A. & Wessels, A. Extracellular matrix and heart development. *Birth Defects Res A Clin Mol Teratol* **91**, 535-550, doi:10.1002/bdra.20810 (2011).
27 Asp, M. *et al.* A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of the Developing Human Heart. *Cell* **179**, 1647-1660 e1619, doi:10.1016/j.cell.2019.11.025 (2019).
28 Suryawanshi, H. *et al.* Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. *Cardiovasc Res* **116**, 1446-1457, doi:10.1093/cvr/cvz257 (2020).
29 Cui, Y. *et al.* Single-Cell Transcriptome Analysis Maps the Developmental Track of the Human Heart. *Cell Rep* **26**, 1934-1950 e1935, doi:10.1016/j.celrep.2019.01.079 (2019).
30 Kuwabara, J. T. *et al.* Regulation of extracellular matrix composition by fibroblasts during perinatal cardiac maturation. *J Mol Cell Cardiol* **169**, 84-95, doi:10.1016/j.yjmcc.2022.05.003 (2022).
31 Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. *Genesis* **45**, 593-605, doi:10.1002/dvg.20335 (2007).
32 Chung, M. I., Bujnis, M., Barkauskas, C. E., Kobayashi, Y. & Hogan, B. L. M. Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell proliferation and differentiation. *Development* **145**, doi:10.1242/dev.163014 (2018).
33 Kanisicak, O. *et al.* Genetic lineage tracing defines myofibroblast origin and function in the injured heart. *Nat Commun* **7**, 12260, doi:10.1038/ncomms12260 (2016).
34 Nagendran, M., Riordan, D. P., Harbury, P. B. & Desai, T. J. Automated cell-type classification in intact tissues by single-cell molecular profiling. *Elife* **7**, doi:10.7554/eLife.30510 (2018).
35 McGinnis, C. S. *et al.* MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices. *Nat Methods* **16**, 619-626, doi:10.1038/s41592-019-0433-8 (2019).
36 Feng, W. *et al.* Single-cell transcriptomic analysis identifies murine heart molecular features at embryonic and neonatal stages. *Nat Commun* **13**, 7960, doi:10.1038/s41467-022-35691-7 (2022).

37 Zhang, D. *et al.* Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis. *Nat Commun* **13**, 6371, doi:10.1038/s41467-022-33734-7 (2022).
38 Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods* **16**, 1289-1296, doi:10.1038/s41592-019-0619-0 (2019).
39 Hao, Y. *et al.* Dictionary learning for integrative, multimodal and scalable single-cell analysis. *Nat Biotechnol* **42**, 293-304, doi:10.1038/s41587-023-01767-y (2024).
40 Aibar, S. *et al.* SCENIC: single-cell regulatory network inference and clustering. *Nat Methods* **14**, 1083-1086, doi:10.1038/nmeth.4463 (2017).
41 Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. *Nat Protoc* **15**, 1484-1506, doi:10.1038/s41596-020-0292-x (2020).
42 Jin, S. *et al.* Inference and analysis of cell-cell communication using CellChat. *Nat Commun* **12**, 1088, doi:10.1038/s41467-021-21246-9 (2021).
43 Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. *Nat Methods* **17**, 159-162, doi:10.1038/s41592-019-0667-5 (2020).


A
E11.5
DAPI
Col1a1
Merge
E14.5
DAPI
Col1a1
Merge
E17.5
DAPI
Col1a1
Merge
P2
DAPI
Col1a1
Merge


C
DAPI
Actn2
DAPI/Actn2/Col1a1
E17.5
Col1a1
Cdh5
DAPI/Cdh5/Col1a1


B
Before E12.5
around E14.5
around E17.5
around P2


D
# of cells contacting with FB
0
2
4
6
8
E17.5 with EC
P3 with EC
E17.5 with CM
P3 with CM


A
Number
Strength
endocardial_ec
vascular_ec
ventricular_cm
epicardial
atrial_cm
fibroblasts
blood
mural_cells
immune
B
LAMININ
PTN
MK
COLLAGEN
FN1
THBS
HSPG
ANGPTL
Fb
Ven_CM
LAMININ
MK
PTN
THBS
FN1
VEGF
TENASCIN
MPZ
ANGPTL
COLLAGEN
Fb
Vas_EC
C
Col6a6 – Sdc4
Col6a6 – Cd44
Col6a6 – (Itga9+Itgb1)
Col6a6 – (Itga2+Itgb1)
Col6a6 – (Itga1+Itgb1)
Col6a3 – Sdc4
Col6a3 – Cd44
Col6a3 – (Itga9+Itgb1)
Col6a3 – (Itga2+Itgb1)
Col6a3 – (Itga1+Itgb1)
Col6a2 – Sdc4
Col6a2 – Cd44
Col6a2 – (Itga9+Itgb1)
Col6a2 – (Itga2+Itgb1)
Col6a2 – (Itga1+Itgb1)
Col6a1 – Sdc4
Col6a1 – Cd44
Col6a1 – (Itga9+Itgb1)
Col6a1 – (Itga2+Itgb1)
Col6a1 – (Itga1+Itgb1)
Col4a2 – Sdc4
Col4a2 – Cd44
Col4a2 – (Itga9+Itgb1)
Col4a2 – (Itga2+Itgb1)
Col4a2 – (Itga1+Itgb1)
Col4a1 – Cd44
Col4a1 – (Itga9+Itgb1)
Col4a1 – (Itga2+Itgb1)
Col4a1 – (Itga1+Itgb1)
Col1a2 – Sdc4
Col1a2 – Cd44
Col1a2 – (Itga9+Itgb1)
Col1a2 – (Itga2+Itgb1)
Col1a2 – (Itga1+Itgb1)
Col1a1 – Sdc4
Col1a1 – Cd44
Col1a1 – (Itga9+Itgb1)
Col1a1 – (Itga2+Itgb1)
Col1a1 – (Itga1+Itgb1)
FB/VenCM
FB/VasEC
p-value
p < 0.01
Commun. Prob.
max
min
D
E11.5
AVC
Ven
E14.5
Sep
Ven
E16.5
Sep
Ven
P3
Sep
Ven
AVC
Ven
Ven
Ven
Ven
Septum
Septum
Septum
E
Strength
VenCM
Erythrocyte
Fb
epi
endo_ec
vas_ec
SA_nodal
Atrial_CM
immune
FN1
Ptn
LAMININ
CDH
Fb
Ven_CM
PTN
MK
LAMININ
CD99
FN1
COLLAGEN
Fb
Vas_EC


A
Pdgfra-CreER
Rosa-mTmG
Tam (200μg/g)
Collect
E13.5
E17.5
DAPI
GFP
Merge
B
Pdgfra-CreER
Rosa-DTA
Tam (200μg/g)
Collect
E13.5
E16.5
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
C
Control
Pdgfra-CreER+/-; Rosa-DTA+/-
Dapi
CD31
Merge
D
μm
***
ns
**
Percentage
LV: Compact
Trabecular
Trabecular / compact
LV
RV
CD31+ area
Control
Pdgfra-CreER+/-
Rosa-DTA+/-
E
Pdgfra-CreER
Rosa-DTA
Tam (200μg/g)
Collect
E15.5
E16.5
E17.5
E18.5
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
F
Control
Pdgfra-CreER+/-;Rosa-DTA+/-
Dapi
CD31
Merge
G
CD31+ area LV
CD31+ area RV
LV compact
LV trabecular
LV trabecular / compact
Control
Pdgfra-CreER+/-
Rosa-DTA+/-


A
E16.5 control
E16.5 ablated
E18.5 control
E18.5 ablated
MULTI-seq barcoding
Sample Pooling
Single cell profiling
Demultiplexing
B
umap2
umap1
Repeat 1
Repeat 2
D
Fb
Percentage
Mural_cell
Percentage
Con_1
Con_2
DTA_1
DTA_2
Con_3
Con_4
DTA_3
DTA_4
E16.5
E18.5
C
Vas_EC
Atrial_CM
Ven_CM
Mural_cell
Endo_EC
Fb
Immune
Epi
umap2
umap1
G1
S
G2M
Con_e16.5
Dta_e16.5
Con_e18.5
Dta_e18.5
E
Fb
umap2
umap1
G1
S
G2M
Con_e16.5
Dta_e16.5
Con_e18.5
Dta_e18.5
Main_fb
Neural_crest_fb
Valve_fb
Dying_fb
F
Ven_CM
Con_e16.5
Dta_e16.5
Con_e18.5
Dta_e18.5
G
G1
S
G2M
Con_1
Con_2
DTA_1
DTA_2
Con_3
Con_4
DTA_3
DTA_4
E16.5
E18.5
H
E16.5
low
high
Con_1
Con_2
Dta_1
Dta_2
I
Upregulated at E16.5_DTA
cell proliferation
tube morphogenesis
sarcomere organization
heart development
Downregulated at E16.5_DTA
mitochondrial ATP transmembrane transport
fatty acid import into cell
mitochondrial membrane permeability
chaperone dependent protein refolding
-log10(P-value)
J
Vas_EC
Con_e16.5
Dta_e16.5
Con_e18.5
Dta_e18.5
K
Ifit1
Iigp1
Gm4070
Igtp
Oasl2
Isg15
Irf7
Ifi44
Rsad2
Usp18
Sp100
Gbp3
Parp14
Psmb8
Trim30a
Rtp4
Lgals3bp
Ifih1
Rnf213
Ddx3y
Ifitm3
Irf9
Xaf1
Acer2
Uty
Gbp7
Bst2
Ifi203
Ddx58
Eif2ak2
Stat1
Samd9l
Ankrd37
Lgals9
Flt1
B2m
Plcb4
Itm2b
Con_1
Con_2
DTA_1
DTA_2
Con_3
Con_4
DTA_3
DTA_4
E16.5
E18.5
L
Upregulated at E16.5_DTA and E18.5 DTA samples
cellular response to exogenous dsRNA
NLRP3 inflammasome assembly
type II interferon-mediated pathway
antiviral innate immune response
interleukin-27-mediated pathway
type I interferon production
-log10(P-value)


A
Control
MK
LAMININ
PTN
IGF
FN1
THBS
VEGF
CDH
NCAM
COLLAGEN
main_fb
vas_ec
ven_cm
Pdgfra-CreER DTA
B
Dapi
Collagen
Merge
E18.5_control
Sep
Ven
Septum
Ven
Pdgfra-CreER DTA
D
E16_VasEC_main_Fb
Ifi44
Gbp3
Igf2
Irf9
Bst2
Parp14
Samd9l
Sp100
Hspe1
Sntb1
Cox7c
Hspa1b
Atp5k
Isg15
Rims2
Polr2l
Hbegf
Wnt11
Wnt4
Il33
Wnt5b
Dkk3
Efemp2
Vsig10
Nlgn1
Prnp
Kitl
Tgm2
Psen1
Cxcl12
Adgre5
Adam9
App
Jam2
Efna4
Cd59a
Regulatory potential
0
0.04
0.08
E
IGF signaling pathway network
Down in dying_Fb
main_fb
valve_like_fb
endo_ec
vas_ec
epi
ven_cm
dying_fb
mural_cell
immune
atrial_CM
EGF signaling pathway network
Up in dying_Fb
C
E16.5_Ven_CM_main_Fb
Ligand activity
Ccnd2
Cnn1
Etfa
Masp1
Ndufb10
Ndufs6
Slc25a4
Unc13b
Grb10
Mical2
Pdlim7
Sema3c
Tagln
Tgm2
Vcan
Cxcl12
Fabp3
Gpc3
Nav3
Abca1
Sod2
Mdh2
Abcg2
Cald1
Hspe1
Kcnd2
Plcb4
Aplp2
Itga9
Ldlrad4
Erbb4
Gria3
Pde7b
Rspo3
Krt18
Meis2
Sfrp1
Acsl1
Arhgap31
Robo1
Fbxl7
Cd55
Cycs
Hspd1
Unc5b
Col1a1
Tgfb1
Col5a1
Col4a1
Igf2
Apoe
Reln
Cd9
Col8a2
Jag1
Anxa2
Calr
Hbegf
Tgfb2
Itm2b
Timp1
Angptl2
Bmp7
Pf4
Bmp4
Ang
Nppa
Low
High
AUPR
Regulatory potential
0
0.1
0.2
0.3


A
Pdgfra-CreER
Rosa-DTA
Tam (10μg/g)
Collect
P1
P2
P3
P4
B
Control
Ablated
C
Control
Ablated
Dapi
CD31
Merge
D
LV compact
LV trabecular
LV trabecular/compact
ns
μm
LV_CD31
RV_CD31
**
Control
Pdgfra-CreER+/-
Rosa-DTA+/-
E
Dapi
Collagen
Merge
Control
Ablated
Sep
Ven
Septum
Ven
F
Pdgfra-CreER
Rosa-DTA
Tam (10μg/g)
Echo/Collect
P3
P4
P5
P17
Control
Ablated
G
Lethal time
Percentage
P11
P12
P13
P15
>P17
H
Control
Ablated
I
Heart rate
Body weight(g)
Heart body ratio (%)
***
ns
EF
FS
Percentage
Control
Pdgfra-CreER+/-
Rosa-DTA+/-


E12.5
DAPI
Col1a1
Merge
E13.5
DAPI
Col1a1
Merge
E15.5
DAPI
Col1a1
Merge
E16.5
DAPI
Col1a1
Merge
E18.5
DAPI
Col1a1
Merge
P0
DAPI
Col1a1
Merge
P3
DAPI
Col1a1
Merge


A E13.5 DAPI
Actn2
DAPI/Actn2/Col1a1
Col1a1
Cdh5
DAPI/Cdh5/Col1a1
B P3 DAPI
Actn2
DAPI/Actn2/Col1a1
Col1a1
Cdh5
DAPI/Cdh5/Col1a1













E **Top 10 genes in each group**

cluster			Main population
7	11	12	
Col9a1	Cdh5	Gfra3	Akap12
Col9a3	Flt1	Sox10	Lsp1
Sall3	Tie1	Foxd3	Tnxb
Hapln1	Kdr	Phox2b	Col3a1
Lef1	Rasip1	Gm12688	Col1a1
Scx	Myct1	Gjc3	Sparc
Spint2	Adgrl4	Mal	Col6a1
Nnat	Gngt2	Chl1	Tcf21
Rspo3	Gimap4	Plekhb1	Col14a1
Ociad2	Gimap1	Kcna1	Col6a2




A
CD1
Fb
umap2
umap1
atrial_cm
ventricular_cm
endocardial_ec
vascular_ec
epicardial
fibroblasts
mural_cells
immune
blood
B
CD1
Main Fb
C
C57BL/6
Fb
D
C57BL/6
Main Fb
E
E9.5
E10.5
E11.5
E12.5
E13.5
E14.5
E15.5
E16.5
E17.5
E18
P0
P1
P2
P3
P4
P5
P7
P9
umap2
umap1
F
LA
LV
RA
RV


A
Extracellular matrix GO:0031012
Stage
LA
LV
RA
RV
E9.5
E10.5
E11.5
E12.5
E13.5
E14.5
E15.5
E16.5
E17.5
E18
P0
P1
P2
P3
P4
P5
P7
P9
G1
G2
G3
G4
Enrichment Score
2
1
0
−1
−2
B
stage
zone
G1
early stage
C
G2
late stage LV&RV
D
G3
late stage LA&RA
E
G4
late stage LA&LV&RV


A
Extracellular matrix GO:0031012
Stage
LA
LV
RA
RV
E9.5
E10.5
E11.5
E12.5
E13.5
E14.5
E15.5
E16.5
E17.5
E18
P0
P1
P2
P3
P4
P5
P7
P9
Enrichment Score
2
1
0
−1
−2
G5


B
stage
zone
G5
late
stage
Gpc4
Anxa5
Cstb
Itgb1
Col4a1
Col4a2
Hmcn1
Srpx2
Thbs2
Gpc6
Ltbp3
Ecm2
Rarres2
Bmp1
Col6a3
Col14a1
Aspn
Sparc
Col5a2
Col3a1
Col1a1
Col1a2
Postn
Tnxb
Chadl
Lamb2
Adamtsl4
Mamdc2
Serping1
Lrrc17
Dcn
Lum
Ctsl
Mmp2
Serpinf1
Ecm1
Thbs3
Itih5
Dpt
Igfbp7
Angptl2
Ogn
Matn2
Lama2
Ltbp4
Ctsd
Scara3


A
Extracellular matrix GO:0031012
C57BL6
LA
LV
RA
RV
Stage
E10.5
E11.5
E12.5
E13.5
E14.5
E15.5
E16.5
E17.5
E18.5
P1
P2
P3
P4
P5
P7
P8
P9
G1
G2
G5
G4
G3
Enrichment Score
2
1
0
−1
−2
B
stage
zone
G1
early stage four chamber
Col18a1
Pkm
Wnt5a
Colec12
Wnt11
Igf2
Egfl7
Reln
Col13a1
Hapln1
Cfdp1
Hcfc1
Hnrnpm
Hsp90aa1
Gsto1
Frem1
Rpsa
Col26a1
Efna5
Svep1
Egflam
Slit2
G2
late stage LV&RV
Lgals9
Col5a1
Col6a1
Col6a2
Nid1
Sparcl1
Col5a3
Serpinb6a
Angptl4
Srpx2
Vwa5a
Adamts5
Adamts14
Pf4
Lamb1
Lamc1
Sema3c
Matn4
Lama4
Thsd4
Adamtsl3
Prelp
G3
late stage LA&RA
Adamts4
Col12a1
Anxa9
Runx1
Adamts1
Thbs1
Lrrc32
Mmp16
Dag1
Plod1
Tgfb2
Mmp17
Npnt
Lgalsl
Spon1
Itgb1
Col4a1
Col4a2
Fn1
Hmcn1
Gpc4
Tnc
Acta2
Ptprz1
G4
late stage LA&LV&RV
Lrig1
Angptl1
Itih2
Tnfrsf11b
Ntn4
Htra1
Pcolce2
Hmcn2
Col4a5
Il16
Col4a4
Ccbe1
Cilp
Lrrn2
Scara3
Adamts8
Col4a3
Olfml2a
Col4a6
Sema6d
Col8a1
Plxdc2
Igf1
Sod3
Adamtsl2
Ltbp2
Mfap4
Cthrc1
Eln
Fbln5
G5
late stage four chamber
Crispld2
Ssc5d
Fgl2
Ccdc80
Ctsl
Cst3
Mgp
Rarres2
S100a13
S100a6
Timp2
Adamtsl4
Col15a1
Serpinf1
Abi3bp
Matn2
Serping1
Mmp2
Dcn
Lum
Anxa5
Pxdn
Col14a1
Loxl1
Col6a3
Lama2
Fbn1
Itih5
Dpt
Igfbp7
Adamts2
Bgn
Ltbp3
Ltbp4
Sparc
Col1a2
Col1a1
Col3a1


A
Ventricular_CM & Main_FB
B
Vas_EC & Main_FB
Log2 mean (Molecule 1, Molecule 2)
E9.5
E10.5
E11.5
E12.5
E13.5
E14.5
E15.5
E16.5
E17.5
E18
P0
P1
P2
P3
P4
P5
P7
P9
−log10(pvalue)
1.5
2.0
2.5
3.0
Log2 mean (Molecule 1, Molecule 2)
4
2
0
−2
2.5
0.0
−2.5


A
(i)
Postn
0 1 2 3 4 5
umap2
umap1
(ii)
Pdgfra
0 1 2 3
B
(i)
Postn-CreER
Rosa-mTmG
(ii)
Tam (200μg/g)
Collect
E13.5
E17.5
DAPI
GFP
Merge


A
Control
Pdgfra-CreER+/-; Rosa-DTA+/-
Dapi
TUNEL
Merge
B
TUNEL positive counts
Ven_pHH3
Atrial_pHH3
Count per mm2
*
**
ns
Control
Pdgfra-CreER+/- Rosa-DTA+/-
C
Control
Pdgfra-CreER+/-; Rosa-DTA+/-
E16.5
LV
DAPI
CD31
Compact
Trabecular

A

E15.5, E16.5, E17.5 Tamoxifen; E18.5 hearvest




A
Pdgfra-CreER
Rosa-DTA
Tam (200µg/g)
Collect
E15.5
E18.5
B
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
C
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
DAPI
CD31
Merge
D
LV compact
LV trabecular
RV compact
RV trabecular
µm
*
ns
ns
ns
E
LV trabecular / compact
RV trabecular / compact
ns
*
F
Ven_1_dose_pHH3
Ven_3 doses_pHH3
counts per mm2
ns
**
Control
Pdgfra-CreER+/-
Rosa-DTA+/-
G
3 doses
Control
3 doses
Pdgfra-CreER+/-
Rosa-DTA+/-
DAPI
Col1a1
Merge


A
Gene number
Counts number
Mitochondria gene percentage
7500
5000
2500
0
60000
40000
20000
0
8
6
4
2
0
con_e16.5
dta_e18.5
con_e18.5
dta_e16.5
B
Fb sub lineage genes
Aldh1a2
Wt1
Hapln1
Sox10
umap2
umap1
C
Dying Fb associated genes
Snhg15
Cebpb
D
Ven_CM
E
Vas_EC
G1
S
G2M


A
Ven_CM_main_Fb
Receptors
Ligands
Acvr1
Bmpr2
Bmpr1a
Acvr2a
Acvr2b
Vldlr
Lrp1
Ldlr
App
Lrp5
Scarb1
Itga6
Insr
Igf1r
Igf2r
Sdc2
Acvr1b
Tgfbr3
Tgfbr1
Tgfbr2
Erbb4
Cd9
Erbb2
Sdc3
Itgb1
Ddr1
Itga1
Cd36
Igsf8
Itga3
Cd44
Itga9
Cd46
Notch2
Plxnb1
Plxnb2
Cd63
Fgfr2
Lpl
Itgb5
Itga5
Itgav
Tlr4
S1pr1
Ror2
Plxna1
Npr2
F11r
Abca1
Dysf
Cd9
Anxa2
Igf2
Itm2b
Jag1
Lin7c
Mpdz
Nppa
Sema6c
Zdhhc5
Hbegf
Has1
Timp1
Pf4
Reln
Calr
Apoe
Tgfb2
Tgfb1
Sema4c
Ang
Bmp7
Bmp4
Col8a2
Col5a1
Col4a1
Col1a1
Edil3
Angptl2
Angptl3


B
VasEC_main_Fb
Receptors
Ligands
Prior interaction potential
0.0 0.4 0.8 1.2 1.6
Ryk
Ror2
Mcam
Ror1
Lrp5
Lrp6
Fzd8
Fzd3
Fzd6
Notch1
Fzd4
Smo
Erbb4
Erbb2
Cd9
Cd44
Cd82
Itga2
Itga1
Ddr1
Cd47
Cd93
Sdc4
Tbxa2r
Adgrg1
Itga9
Itga6
Sdc3
Ptprb
Sdc1
Tnfrsf21
Bace1
Flt1
Notch2
Ncstn
Notch4
Psen1
Jam3
F11r
Jam2
Itgb5
Itgav
Itgb1
Ptprs
Ptprd
Ptprf
Epha7
Epha2
Epha4
Plxna2
Plxna4
Cadm1
Nectin3
Aqp1
Plscr4
Ackr3
Cxcr4
Stab1
Nrxn3
Ncam1
Mertk
Kremen1
Kit
Kdr
Il6st
Cd55
Il1rap
Cadm1
Adgre5
Cd59a
Dkk3
Efemp2
Efna4
Gas6
Hbegf
Il33
Kitl
Lrrc4b
Ltbp3
Prnp
Scube2
Sema6a
Vsig10
Psen1
App
Nlgn2
Nlgn1
Tgm2
Mdk
Cxcl12
Jam2
Adam9
Col4a6
Wnt5b
Wnt11
Wnt4
Wnt5a
Prior interaction potential
0.0 0.4 0.8 1.2 1.6

A

Down in dying_Fb







B

Up in dying_Fb








A
Pdgfra-CreER
Rosa-DTA
Tam (10μg/g)
Collect
P1
P4
B
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
C
DAPI
CD31
Merge
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
D
LV compact thickness
LV trabecular thickness
RV compact thickness
RV trabecular thickness
ns
μm
Control
Pdgfra-CreER+/-
Rosa-DTA+/-
E
LV trabecular / compact
RV trabecular / compact
F
Ven_pHH3_1dose_tam
G
Ven_pHH3_3dose_tam
counts per mm2


A
Dapi
Collagen
Merge
P18_control
RV
Septum
LV
B
Dapi
Collagen
Merge
P18_3dose_Tam
Pdgfra-CreER;DTA
RV
Septum
LV


A
Brain
Lung
Kidney
Liver
Control
Pdgfra-CreER+/-;
Rosa-DTA+/-
B
Dapi
Collagen
Merge
P18_control_lung
P18_3dose_Tam_lung
Pdgfra-CreER;DTA


80
60
40
20
0
EF
ns
40
30
20
10
0
FS
ns
Control
Pdgfra-CreER+/-
Rosa-DTA+/-